https://www.biopharmawatch.com/news/MRK/merck-presents-one-year-results-pivotal-phase-2b-3-brunello BiopharmaWatch en 2026-10-10T22:10:00.000Z Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026 https://www.biopharmawatch.com/news/MRK/merck-brunello-study-results-remigromig-dme BiopharmaWatch en 2026-10-10T22:10:00.000Z Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026 https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-preclinical-data-lb-102-ecnp-congress BiopharmaWatch en 2026-10-10T12:00:00.000Z LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-presentation-breakthrough-t1d-congress-2026 BiopharmaWatch en 2026-10-10T12:00:00.000Z vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026 https://www.biopharmawatch.com/news/MNKD/mannkind-furoscix-readyflow-hfsa-2026 BiopharmaWatch en 2026-10-10T00:00:00.000Z MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-announces-new-employment-inducement-grants-20261009 BiopharmaWatch en 2026-10-09T20:35:00.000Z Arcus Biosciences Announces New Employment Inducement Grants https://www.biopharmawatch.com/news/CCEL/cryo-cell-reports-fiscal-q3-2026-results BiopharmaWatch en 2026-10-09T20:30:00.000Z Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/EVH/evolent-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-09T20:30:00.000Z Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/AEON/aeon-biopharma-inducement-grant-nyse-american BiopharmaWatch en 2026-10-09T20:15:29.000Z AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 https://www.biopharmawatch.com/news/PCVX/vaxcyte-closes-1-15-billion-offerings BiopharmaWatch en 2026-10-09T20:05:09.000Z Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes https://www.biopharmawatch.com/news/ACH/accendra-health-nyse-listing-standard-notice BiopharmaWatch en 2026-10-09T20:05:00.000Z Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-announces-inducement-grants-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-10-09T20:05:00.000Z Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ASTH/astrana-health-q3-financial-results-2026 BiopharmaWatch en 2026-10-09T20:05:00.000Z Astrana Health, Inc. Schedules 2026 Third Quarter Financial Results Release and Conference Call https://www.biopharmawatch.com/news/AGEN/agenus-participate-chardan-healthcare-conference BiopharmaWatch en 2026-10-09T19:23:00.000Z Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference https://www.biopharmawatch.com/news/VRTX/vertex-alytfrek-data-north-american-cystic-fibrosis-conference BiopharmaWatch en 2026-10-09T17:15:00.000Z Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference https://www.biopharmawatch.com/news/BIAF/wallachbeth-capital-announces-closing-bioaffinity-technologies-4-million-registered-direct BiopharmaWatch en 2026-10-09T16:30:00.000Z WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/RGNT/regentis-biomaterials-thinkequity-conference-2026 BiopharmaWatch en 2026-10-09T16:05:00.000Z Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-inc-announces-closing-4-million-registered-direct-financing BiopharmaWatch en 2026-10-09T15:37:00.000Z bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/BMRN/biomarin-advances-achondroplasia-hypochondroplasia-treatment BiopharmaWatch en 2026-10-09T13:05:00.000Z BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting https://www.biopharmawatch.com/news/HCWB/hcw-biologics-ind-application-solid-tumors BiopharmaWatch en 2026-10-09T13:00:00.000Z HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors https://www.biopharmawatch.com/news/MLYS/mineralys-lorundrostat-aha-hypertension-sessions-2026 BiopharmaWatch en 2026-10-09T13:00:00.000Z Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026 https://www.biopharmawatch.com/news/CLGN/collplant-announces-private-placement-3-7-million BiopharmaWatch en 2026-10-09T13:00:00.000Z COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT https://www.biopharmawatch.com/news/RPRX/royalty-pharma-third-quarter-2026-results BiopharmaWatch en 2026-10-09T12:53:25.000Z Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026 https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-greg-dipasquale-cco BiopharmaWatch en 2026-10-09T12:30:00.000Z Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer https://www.biopharmawatch.com/news/ARQT/arcutis-zoryve-data-eadv-fall-clinical BiopharmaWatch en 2026-10-09T12:00:27.000Z Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-q3-2026-earnings-release BiopharmaWatch en 2026-10-09T12:00:00.000Z Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call https://www.biopharmawatch.com/news/NTRA/fda-breakthrough-device-natera-multi-cancer-assay BiopharmaWatch en 2026-10-09T12:00:00.000Z FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-cvr-agreement-shareholder-participation BiopharmaWatch en 2026-10-09T12:00:00.000Z Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-revera-301-european-participant BiopharmaWatch en 2026-10-09T12:00:00.000Z Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-maxim-growth-summit-2026 BiopharmaWatch en 2026-10-09T12:00:00.000Z Nuvectis Pharma to Participate in the Maxim Growth Summit 2026 https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-acg-ueg-conferences-2026 BiopharmaWatch en 2026-10-09T12:00:00.000Z Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-relaunches-irulya-therapeutics BiopharmaWatch en 2026-10-09T12:00:00.000Z Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease https://www.biopharmawatch.com/news/FLNA/filana-therapeutics-maxim-growth-summit-2026 BiopharmaWatch en 2026-10-09T12:00:00.000Z Filana Therapeutics to Participate in the 2026 Maxim Growth Summit https://www.biopharmawatch.com/news/TLX/profound-telix-co-education-agreement-psma-prostate-care BiopharmaWatch en 2026-10-09T11:45:00.000Z Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care